Prevention of maternal–fetal transmission of cytomegalovirus after primary maternal infection in the first trimester by biweekly hyperimmunoglobulin administration. (8th February 2019)

• Record Type: Journal Article
• Authors: Kagan, K. O.; Enders, M.; Schampera, M. S.; Baeumel, E.; Hoopmann, M.; Geipel, A.; Berg, C.; Goelz, R.; De Catte, L.; Wallwiener, D.; Brucker, S.; Adler, S. P.; Jahn, G.; Hamprecht, K.
• Is Part Of: Ultrasound in obstetrics & gynecology. Volume 53:Number 3(2019)
• Page Start: 383
• Page End: 389
• Publication Date: 2019-02-08
• Subjects: CMV -- cytomegalovirus -- first trimester -- hyperimmunoglobulin -- pregnancy; Ultrasonics in obstetrics -- Periodicals; Generative organs, Female -- Diseases -- Diagnosis -- Periodicals; Diagnosis, Ultrasonic -- Periodicals; Genital Diseases, Female -- ultrasonography -- Periodicals; Ultrasonography, Prenatal -- Periodicals; 618.047543
• DOI: 10.1002/uog.19164
• Languages: English
• ISSNs: 0960-7692

Abstract

ABSTRACT: Objective: To examine the efficacy of biweekly hyperimmunoglobulin (HIG) administration to prevent maternal–fetal transmission of cytomegalovirus (CMV) in women with primary first‐trimester CMV infection. Methods: This was a prospective observational study of women with confirmed primary CMV infection in the first trimester who had the first HIG administration at or before 14 weeks' gestation. All women had biweekly HIG treatment until 20 weeks' gestation at a dose of 200 IU/kg of maternal body weight. Each subject underwent amniocentesis at least 6 weeks after first presentation at about 20 weeks. Primary outcome was maternal–fetal transmission at the time of amniocentesis, and secondary outcome was the frequency of congenital CMV infection at birth. The results were compared with a historic cohort of women with first‐trimester CMV infection who did not undergo HIG treatment and who had amniocentesis at about 20 weeks. Results: Subjects were 40 pregnant women with a primary CMV infection, with a median gestational age at first presentation of 9.6 (range, 5.1–14.3) weeks. On average, HIG administration started at 11.1 weeks and continued until 16.6 weeks. Within this interval, HIG was administered between two and six times in each patient. While CMV immunoglobulin‐G (IgG) monitoring showed periodic fluctuations during biweekly HIG administration cycles, high CMV‐IgG avidity indices remained stable over the whole treatment period. Maternal–fetal transmission before amniocentesis occurred in only one of the 40 cases (2.5% (95% CI, 0–13.2%)). At delivery, two additional subjects were found to have had late‐gestation transmission. Considering all three cases with maternal–fetal transmission, the transmission rate was 7.5% (95% CI, 1.6–20.4%) in our 40 cases. All infected neonates were asymptomatic at birth. The matched historical control group consisted of 108 pregnancies. Thirty‐eight transmissions (35.2% (95% CI, 26.2–45.0%)) occurred in the control group, which was significantly higher ( P < 0.0001) than the transmission rate in the HIG treatment group. Conclusion: After a primary maternal CMV infection in the first trimester, biweekly HIG administration at a dose of 200 IU/kg prevents maternal–fetal transmission up to 20 weeks' gestation. Copyright © 2018 ISUOG. Published by John Wiley & Sons Ltd.